Wall Street analysts forecast that Genocea Biosciences Inc (NASDAQ:GNCA) will announce earnings of ($0.45) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.39). Genocea Biosciences posted earnings of ($0.72) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 37.5%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 7th.
According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($2.36) per share for the current year, with EPS estimates ranging from ($2.77) to ($2.13). For the next financial year, analysts forecast that the company will report earnings of ($1.64) per share, with EPS estimates ranging from ($1.87) to ($1.21). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, July 25th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.02).
Several brokerages have recently weighed in on GNCA. Stifel Nicolaus began coverage on shares of Genocea Biosciences in a research note on Monday, July 8th. They issued a “buy” rating for the company. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Wednesday, July 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 target price (down from $42.00) on shares of Genocea Biosciences in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Buy” and an average price target of $18.25.
In other Genocea Biosciences news, major shareholder Peter W. Sonsini bought 2,857,142 shares of the company’s stock in a transaction on Monday, June 24th. The shares were bought at an average cost of $3.50 per share, with a total value of $9,999,997.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.33% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of GNCA. Morgan Stanley acquired a new stake in shares of Genocea Biosciences during the second quarter worth $26,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $40,000. Wedbush Securities Inc. acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $43,000. Citadel Advisors LLC acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $68,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $84,000.
Shares of GNCA stock traded down $0.11 on Wednesday, hitting $3.01. The stock had a trading volume of 364 shares, compared to its average volume of 170,406. The firm has a market capitalization of $81.58 million, a price-to-earnings ratio of -0.82 and a beta of 2.40. The stock’s 50 day moving average is $3.53 and its 200-day moving average is $2.18. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.96 and a current ratio of 5.96. Genocea Biosciences has a 52-week low of $2.24 and a 52-week high of $11.28.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Story: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.